1
|
Cutts A, Savoie H, Hammer MF, Schreiber J, Grayson C, Luzon C, Butterfield N, Pimstone SN, Aycardi E, Harden C, Yonan C, Jen E, Nguyen T, Carmack T, Haubenberger D. Clinical Characteristics and Treatment Experience of Individuals with SCN8A Developmental and Epileptic Encephalopathy (SCN8A-DEE): Findings from an Online Caregiver Survey. Seizure 2022; 97:50-57. [DOI: 10.1016/j.seizure.2022.03.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2021] [Revised: 03/04/2022] [Accepted: 03/09/2022] [Indexed: 10/18/2022] Open
|
2
|
Farber RH, Angelov A, Kim K, Carmack T, Thai-Cuarto D, Roberts E. Clinical development of valbenazine for tics associated with Tourette syndrome. Expert Rev Neurother 2021; 21:393-404. [PMID: 33682568 DOI: 10.1080/14737175.2021.1898948] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Introduction: Significant need exists for effective, well-tolerated pharmacologic treatments for Tourette syndrome (TS). Medications that inhibit vesicular monoamine transporters (i.e. VMAT2 inhibitors) downregulate presynaptic packaging and release of dopamine into the neuronal synapse and are effective in treating hyperkinetic movement disorders such as Huntington's chorea and tardive dyskinesia (TD); thus, they may be useful in treating TS.Areas covered: This review describes the clinical program evaluating the safety and efficacy of valbenazine in the treatment of involuntary tics associated with TS in adult and pediatric subjects. While there was a trend in the 6 completed trials toward greater improvement in valbenazine-treated versus placebo subjects on the primary efficacy endpoint (Yale Global Tic Severity Scale Total Tic Score), this difference did not reach statistical significance. Valbenazine was generally well-tolerated in the studies, and treatment-emergent adverse events were consistent with valbenazine studies in TD.Expert opinion: Due to the failure to meet the primary endpoint in these trials, further investigation of valbenazine for TS is unlikely. Given the need for safe and effective TS therapies and the key role of VMAT2 in modulating dopaminergic activity, it is reasonable for future studies to investigate other VMAT2 inhibitors as potential treatments for TS.
Collapse
Affiliation(s)
- Robert H Farber
- Medical Affairs, Neurocrine Biosciences, Inc., San Diego, CA, USA
| | - Angel Angelov
- Medical Affairs, Neurocrine Biosciences, Inc., San Diego, CA, USA
| | - Kristine Kim
- Medical Affairs, Neurocrine Biosciences, Inc., San Diego, CA, USA
| | - Tara Carmack
- Medical Affairs, Neurocrine Biosciences, Inc., San Diego, CA, USA
| | - Dao Thai-Cuarto
- Medical Affairs, Neurocrine Biosciences, Inc., San Diego, CA, USA
| | - Eiry Roberts
- Medical Affairs, Neurocrine Biosciences, Inc., San Diego, CA, USA
| |
Collapse
|
3
|
Siegert S, Yonan C, Longo N, Cratty H, Nicosia M, Sampalis J, Carmack T, Dhanda R, Farahmand K, Lundt L, Angelov A, Goldberg E. Real-world evaluation of patient characteristics and disease management in long-term valbenazine treatment in adults with Tardive dyskinesia. Parkinsonism Relat Disord 2020. [DOI: 10.1016/j.parkreldis.2020.06.426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
4
|
Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, Dörner T, Cardiel MH, Bruce IN, Gomez E, Carmack T, DeLozier AM, Janes JM, Linnik MD, de Bono S, Silk ME, Hoffman RW. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 2018; 392:222-231. [PMID: 30043749 DOI: 10.1016/s0140-6736(18)31363-1] [Citation(s) in RCA: 325] [Impact Index Per Article: 54.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/15/2018] [Revised: 06/02/2018] [Accepted: 06/08/2018] [Indexed: 12/21/2022]
Abstract
BACKGROUND Patients with systemic lupus erythematosus have substantial unmet medical need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we hypothesised might have therapeutic benefit in patients with systemic lupus erythematosus. METHODS In this double-blind, multicentre, randomised, placebo-controlled, 24-week phase 2 study, patients were recruited from 78 centres in 11 countries. Eligible patients were aged 18 years or older, had a diagnosis of systemic lupus erythematosus, and had active disease involving skin or joints. We randomly assigned patients (1:1:1) to receive once-daily baricitinib 2 mg, baricitinib 4 mg, or placebo for 24 weeks. The primary endpoint was the proportion of patients achieving resolution of arthritis or rash at week 24, as defined by Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K). Efficacy and safety analyses included all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, number NCT02708095. FINDINGS Between March 24, 2016, and April 27, 2017, 314 patients were randomly assigned to receive placebo (n=105), baricitinib 2 mg (n=105), or baricitinib 4 mg (n=104). At week 24, resolution of SLEDAI-2K arthritis or rash was achieved by 70 (67%) of 104 patients receiving baricitinib 4 mg (odds ratio [OR] vs placebo 1·8, 95% CI 1·0-3·3; p=0·0414) and 61 (58%) of 105 patients receiving baricitinib 2 mg (OR 1·3, 0·7-2·3; p=0·39). Adverse events were reported in 68 (65%) patients in the placebo group, 75 (71%) patients in the baricitinib 2 mg group, and 76 (73%) patients in the baricitinib 4 mg group. Serious adverse events were reported in ten (10%) patients receiving baricitinib 4 mg, 11 (10%) receiving baricitinib 2 mg, and five (5%) receiving placebo; no deaths were reported. Serious infections were reported in six (6%) patients with baricitinib 4 mg, two (2%) with baricitinib 2 mg, and one (1%) with placebo. INTERPRETATION The baricitinib 4 mg dose, but not the 2 mg dose, significantly improved the signs and symptoms of active systemic lupus erythematosus in patients who were not adequately controlled despite standard of care therapy, with a safety profile consistent with previous studies of baricitinib. This study provides the foundation for future phase 3 trials of JAK1/2 inhibition with baricitinib as a new potential oral therapy for systemic lupus erythematosus. FUNDING Eli Lilly and Company.
Collapse
Affiliation(s)
- Daniel J Wallace
- Division of Rheumatology, Cedars-Sinai Medical Center, University of California at Los Angeles, Los Angeles, CA, USA.
| | - Richard A Furie
- Division of Rheumatology, Zucker School of Medicine at Hofstra, Northwell, New York, NY, USA
| | - Yoshiya Tanaka
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Kenneth C Kalunian
- Division of Rheumatology, University of California at San Diego School of Medicine, La Jolla, CA, USA
| | - Marta Mosca
- Division of Rheumatology, University of Pisa, Pisa, Italy
| | - Michelle A Petri
- Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Thomas Dörner
- Division of Rheumatology, Charite Universitätsmedizin Berlin, Berlin, Germany
| | - Mario H Cardiel
- Centro de Investigación Clínica de Morelia SC, Morelia, México
| | - Ian N Bruce
- Arthritis Research UK Centre for Epidemiology, Faculty of Biology, Medicine and Health, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
| | - Elisa Gomez
- Eli Lilly and Company, Indianapolis, IN, USA
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Genovese MC, Kremer JM, Kartman CE, Schlichting DE, Xie L, Carmack T, Pantojas C, Sanchez Burson J, Tony HP, Macias WL, Rooney TP, Smolen JS. Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis. Rheumatology (Oxford) 2018; 57:900-908. [PMID: 29415145 PMCID: PMC5913638 DOI: 10.1093/rheumatology/kex489] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Revised: 09/28/2017] [Indexed: 12/11/2022] Open
Abstract
Objective RA patients who have failed biologic DMARDs (bDMARDs) represent an unmet medical need. We evaluated the effects of baseline characteristics, including prior bDMARD exposure, on baricitinib efficacy and safety. Methods RA-BEACON patients (previously reported) had moderate to severe RA with insufficient response to one or more TNF inhibitor and were randomized 1:1:1 to once-daily placebo or 2 or 4 mg baricitinib. Prior bDMARD use was allowed. The primary endpoint was a 20% improvement in ACR criteria (ACR20) at week 12 for 4 mg vs placebo. An exploratory, primarily post hoc, subgroup analysis evaluated efficacy at weeks 12 and 24 by ACR20 and Clinical Disease Activity Index (CDAI) ⩽10. An interaction P-value ⩽0.10 was considered significant, with significance at both weeks 12 and 24 given more weight. Results The odds ratios predominantly favored baricitinib over placebo and were generally similar to those in the overall study (3.4, 2.4 for ACR20 weeks 12 and 24, respectively). Significant quantitative interactions were observed for baricitinib 4 mg vs placebo at weeks 12 and 24: ACR20 by region (larger effect Europe) and CDAI ⩽10 by disease duration (larger effect ⩾10 years). No significant interactions were consistently observed for ACR20 by age; weight; disease duration; seropositivity; corticosteroid use; number of prior bDMARDs, TNF inhibitors or non-TNF inhibitors; or a specific prior TNF inhibitor. Treatment-emergent adverse event rates, including infections, appeared somewhat higher across groups with greater prior bDMARD use. Conclusion Baricitinib demonstrated a consistent, beneficial treatment effect in bDMARD-refractory patients across subgroups based on baseline characteristics and prior bDMARD use. Trial registration ClinicalTrials.gov (https://clinicaltrials.gov/), NCT01721044.
Collapse
Affiliation(s)
- Mark C Genovese
- Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA
| | - Joel M Kremer
- Center for Rheumatology, Albany Medical College, Albany, NY
| | - Cynthia E Kartman
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | | | - Li Xie
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | - Tara Carmack
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | | | | | - Hans-Peter Tony
- Department of Rheumatology and Clinical Immunology, University Hospital of Würzburg, Würzburg, Germany
| | - William L Macias
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | - Terence P Rooney
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | - Josef S Smolen
- Division of Rheumatology, Department of Medicine, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
6
|
Schiff M, Takeuchi T, Fleischmann R, Gaich CL, DeLozier AM, Schlichting D, Kuo WL, Won JE, Carmack T, Rooney T, Durez P, Shaikh S, Hidalgo RP, van Vollenhoven R, Zerbini CAF. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Res Ther 2017; 19:208. [PMID: 28923098 PMCID: PMC5604362 DOI: 10.1186/s13075-017-1410-1] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2017] [Accepted: 08/25/2017] [Indexed: 02/06/2023] Open
Abstract
Background This study evaluates patient-reported outcomes (PROs) in a double-blind, phase III study of baricitinib as monotherapy or combined with methotrexate (MTX) in patients with active rheumatoid arthritis (RA) with no or minimal prior conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and naïve to biological DMARDs. Methods Patients were randomized 4:3:4 to MTX administered once weekly (N = 210), baricitinib monotherapy (4 mg once daily (QD), N = 159), or combination of baricitinib (4 mg QD) and MTX (baricitinib + MTX, N = 215). PROs included the Patient’s Global Assessment of Disease Activity (PtGA), patient's assessment of pain, Health Assessment Questionnaire-Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), duration of morning joint stiffness (MJS), worst joint pain, worst tiredness, Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA), Short Form 36 version 2, Acute (SF-36); and EuroQol 5-Dimensions (EQ-5D) Health State Profile. Comparisons were assessed with analysis of covariance (ANCOVA) and logistic regression models. Results Compared to MTX, patients in both baricitinib groups reported greater improvement (p ≤ 0.01) in HAQ-DI, PtGA, pain, fatigue, worst join pain, SF-36 physical component score, and EQ-5D at weeks 24 and 52. For the SF-36 mental component score, patients in both baricitinib groups reported statistically significant improvements (p ≤ 0.01) at week 52 compared to MTX-treated patients. Statistically significant improvements (p ≤ 0.05) were observed with the WPAI-RA for the baricitinib groups vs. MTX at week 24 and for the WPAI-RA daily activity and work productivity measures for baricitinib + MTX at week 52. Conclusions In this study, baricitinib alone or in combination with MTX, when used as initial therapy, resulted in significant improvement compared to MTX in the majority of the pre-specified PRO measures. Trial Registration ClinicalTrials.gov, NCT01711359. Registered on 18 October 2012.
Collapse
Affiliation(s)
- Michael Schiff
- University of Colorado School of Medicine, Denver, CO, 80045, USA.
| | | | - Roy Fleischmann
- Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, 75231, USA
| | | | | | | | - Wen-Ling Kuo
- Eli Lilly and Company, Indianapolis, IN, 46285, USA
| | - Ji-Eon Won
- Eli Lilly and Company, Seoul, Republic of Korea
| | - Tara Carmack
- Eli Lilly and Company, Indianapolis, IN, 46285, USA
| | | | - Patrick Durez
- Service et Pôle de Rhumatologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium.,Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Rheumatology, Brussels, Belgium
| | | | | | | | | |
Collapse
|
7
|
Al-Yasiri AY, Khoobchandani M, Cutler CS, Watkinson L, Carmack T, Smith CJ, Kuchuk M, Loyalka SK, Lugão AB, Katti KV. Mangiferin functionalized radioactive gold nanoparticles (MGF-198AuNPs) in prostate tumor therapy: green nanotechnology for production, in vivo tumor retention and evaluation of therapeutic efficacy. Dalton Trans 2017; 46:14561-14571. [DOI: 10.1039/c7dt00383h] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
We report here production of MGF-198AuNPs and its application for prostate tumor therapy.
Collapse
Affiliation(s)
- A. Y. Al-Yasiri
- Nuclear Science and Engineering Institute (NSEI)
- University of Missouri
- Columbia
- USA
| | - M. Khoobchandani
- Department of Radiology
- Institute of Green Nanotechnology
- University of Missouri
- One Hospital Drive
- Columbia
| | - C. S. Cutler
- Nuclear Science and Engineering Institute (NSEI)
- University of Missouri Research Reactor (MURR)
- University of Missouri
- Columbia
- USA
| | - L. Watkinson
- Harry S. Truman Memorial Veterans Hospital
- University of Missouri
- One Hospital Drive
- Columbia
- USA
| | - T. Carmack
- Harry S. Truman Memorial Veterans Hospital
- University of Missouri
- One Hospital Drive
- Columbia
- USA
| | - C. J. Smith
- Department of Radiology
- Harry S. Truman Memorial Veterans Hospital
- University of Missouri
- One Hospital Drive
- Columbia
| | - M. Kuchuk
- University of Missouri Research Reactor (MURR)
- University of Missouri
- One Hospital Drive
- Columbia
- USA
| | - S. K. Loyalka
- Nuclear Science and Engineering Institute (NSEI)
- University of Missouri
- Columbia
- USA
| | - A. B. Lugão
- Nuclear and Energy Research Institute – IPEN/CNEN/Sao Paulo
- Brazil
| | - K. V. Katti
- Nuclear Science and Engineering Institute (NSEI)
- Department of Radiology
- Institute of Green Nanotechnology
- University of Missouri Research Reactor (MURR)
- Harry S. Truman Memorial Veterans Hospital
| |
Collapse
|
8
|
Schiff M, Takeuchi T, Gaich C, DeLozier A, Schlichting D, Kuo WL, Durez P, Carmack T, Won JE, Fleischmann R. THU0623 Patient-Reported Outcomes from A Phase 3 Study of Baricitinib in Patients with Early Rheumatoid Arthritis Who Had Received Limited or No Treatment with Disease-Modifying anti-Rheumatic Drugs: Table 1. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.1248] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
9
|
Katti K, Shukla R, Chanda N, Zambre A, Katti K, Upendran A, Smith C, Lever J, Cutler C, Robertson D, Watkinson D, Caldwell C, Carmack T, Kannan R. SP-0593 GREEN NANOTECHNOLOGY GENERATES GOLD NANOPARTICLES (AUNP-EGCG): IMPLICATIONS IN PROSTATE TUMOR THERAPY. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)70931-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|